Pharma Firm Hit by US Tariffs & High Costs

Hartmann, a German pharmaceutical company, is facing significant financial challenges due to US tariffs on imported drugs and rising production costs. This has negatively impacted their balance sheet, raising concerns about profitability and potential market share loss. The situation underscores the vulnerability of European pharmaceutical companies to international trade disputes and economic pressures.

Summarized from the sources above. Read the originals for the full story.